BioSpace News Archive

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the pricing of the underwritten public secondary offering of 11,831,496 shares of its common stock held by Sanofi at a price of $515.00 per share

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the pricing of a public offering of 133,333,333 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 133,333,333 common shares, at a combined public offering price of $0.15 per share and accompanying warrant

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in June: Jefferies Global Healthcare Conference Date: Tuesday, June 2, 2020 Fireside chat: 1:30 p.m. ET Goldman Sachs 41st Annual Global Heal

Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced that Dr. Ruth Ben Yakar, Chief Executive Officer of Biosight, will present at the Jefferies 2020 Virtual Healthcare Conference taking place from June 2-4, 2020. The company will also be available for one-on-one meetings. Presentation Details: Date: Wednesday, June 3 Time: 10 a

Appoints John Purpura as interim Chief Executive Officer. Reiterates intention to announce top-line data from Phase 3 FOCUS trial by year-end Accelerates shift to commercialization planning NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that the Board of Directors appointed John Purpura as interim Chief Executive Officer. Dr. Roge

Beyond Air, Inc. announced that Health Canada approved the use of the LungFit™ system for a study in hospitalized patients diagnosed with COVID-19 caused by the severe acute respiratory syndrome coronavirus 2.

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com ), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that its Vice President, Scientific Affairs, Dr. Robin A. Robinson will now serve in a new and expanded full-time role as the Company’s Chief Scientific Officer. Prior to joining RenovaCare, Dr. Robinson served as founding Director of the Bio

Emmes today announced that its data and statistical analysis work for the Adaptive COVID-19 Treatment Trial (ACTT) played an important role in the accelerated timetable to evaluate remdesivir’s effectiveness in treating hospitalized CO

- Phase 2b ADVISE trial evaluating etrasimod in atopic dermatitis (AD) enrollment complete, meeting the high end of targeted enrollment range, topline data expected Q4 2020 - Etrasimod ELEVATE UC Program remains on track - Updated guidance for newly initiated trials, and certain trials in planning phase